G Montalescot

Summary

Country: France

Publications

  1. ncbi request reprint A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Gilles Montalescot
    Institut de Cardiologie Pitié Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris APHP, Paris, France
    J Am Coll Cardiol 48:931-8. 2006
  2. ncbi request reprint STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
    Gilles Montalescot
    Institut de Cardiologie and INSERM U856, Pitie Salpetriere University Hospital, AP HP, 47 Boulevard de l Hopital, Paris 75013, France
    Eur Heart J 28:1409-17. 2007
  3. doi request reprint Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
  4. doi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
  5. pmc Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
    G Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Heart 90:e37. 2004
  6. ncbi request reprint Low molecular weight heparin after mechanical heart valve replacement
    G Montalescot
    Departments of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circulation 101:1083-6. 2000
  7. ncbi request reprint Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
    G Montalescot
    Department of Cardiology, Pitie Salpetriere Hospital, Paris
    J Am Coll Cardiol 36:110-4. 2000
  8. ncbi request reprint Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study
    Gilles Montalescot
    Gilles Montalescot, Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Blvd de l Hopital, 75013, Paris, France
    Int J Cardiol 129:379-87. 2008
  9. ncbi request reprint Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial
    G Montalescot
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circulation 98:294-9. 1998
  10. ncbi request reprint Preserving cardiac function in the hypertensive patient: why renal parameters hold the key
    Gilles Montalescot
    Cardiac Care Unit, Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 26:2616-22. 2005

Collaborators

Detail Information

Publications151 found, 100 shown here

  1. ncbi request reprint A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Gilles Montalescot
    Institut de Cardiologie Pitié Salpêtriére University Hospital, Assistence Publique Hôpiteux de Paris APHP, Paris, France
    J Am Coll Cardiol 48:931-8. 2006
    ..We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs)...
  2. ncbi request reprint STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry)
    Gilles Montalescot
    Institut de Cardiologie and INSERM U856, Pitie Salpetriere University Hospital, AP HP, 47 Boulevard de l Hopital, Paris 75013, France
    Eur Heart J 28:1409-17. 2007
    ..The aim of this study was to describe the management and outcomes using 'real-world' data taking the new definition of acute myocardial infarction into account...
  3. doi request reprint Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
    Gilles Montalescot
    Institut de Cardiologie AP HP and INSERM Unit no 856, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 29:462-71. 2008
    ..To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding...
  4. doi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial
    Gilles Montalescot
    Institut du Coeur, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    JACC Cardiovasc Interv 2:1083-91. 2009
    ..Our purpose was to evaluate long-term mortality and identify factors associated with 1-year mortality in patients who underwent elective percutaneous coronary intervention (PCI)...
  5. pmc Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
    G Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Heart 90:e37. 2004
    ..To this aim, a task force for primary PCI in AMI was formed to develop a set of recommendations to complement and assist clinical judgment. This paper represents the product of their recommendations...
  6. ncbi request reprint Low molecular weight heparin after mechanical heart valve replacement
    G Montalescot
    Departments of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circulation 101:1083-6. 2000
    ..We report here the first large and comparative series of consecutive patients anticoagulated with low molecular weight heparin (LMWH) after mechanical heart valve replacement...
  7. ncbi request reprint Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
    G Montalescot
    Department of Cardiology, Pitie Salpetriere Hospital, Paris
    J Am Coll Cardiol 36:110-4. 2000
    ..We tested the hypothesis that different anticoagulant treatments may produce different platelet effects and von Willebrand factor (vWf) release in unstable angina...
  8. ncbi request reprint Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study
    Gilles Montalescot
    Gilles Montalescot, Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Blvd de l Hopital, 75013, Paris, France
    Int J Cardiol 129:379-87. 2008
    ..This study aimed to identify predictors of adverse clinical or angiographic complications following PCI in patients from many different countries...
  9. ncbi request reprint Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial
    G Montalescot
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circulation 98:294-9. 1998
    ....
  10. ncbi request reprint Preserving cardiac function in the hypertensive patient: why renal parameters hold the key
    Gilles Montalescot
    Cardiac Care Unit, Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Eur Heart J 26:2616-22. 2005
    ....
  11. ncbi request reprint Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study)
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Groupe Hospitalier Pitié Salpêtrière Hospital, AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    Am J Cardiol 91:925-30. 2003
    ..vWF and its receptor glycoprotein Ib/IX play a key role in acute coronary syndromes. vWF is linked to inflammation and, like glycoprotein Ib/IX, is affected more favorably by the LWMHs than by UFH...
  12. ncbi request reprint Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis
    Gilles Montalescot
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    JAMA 292:362-6. 2004
    ..No systematic reviews have comprehensively examined the effects of early vs delayed administration of these agents...
  13. doi request reprint Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants
    Gilles Montalescot
    Institut de Cardiogie, Centre Hospitalier Universitarie Pitié Salpetrèire, Paris, France
    Clin Appl Thromb Hemost 15:183-96. 2009
    ..Future trials should report the rates of periprocedural complications when assessing the safety of novel anticoagulation therapies in PCI...
  14. pmc Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction
    G Montalescot
    Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Heart 90:676-7. 2004
  15. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
    G Montalescot
    Division of Cardiology, Pitie Salpetriere Hospital, Paris, France
    N Engl J Med 344:1895-903. 2001
    ....
  16. ncbi request reprint Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE)
    Gilles Montalescot
    Service de cardiologie, Pitie Salpetriere Hospital, Paris, France
    Catheter Cardiovasc Interv 60:360-7. 2003
    ..4% among patients who received neither GP IIb/IIIa inhibitors nor a stent, compared to patients who received both GP IIb/IIIa inhibitors and a stent (7.3%), GP IIb/IIIa inhibitors alone (12.8%), or a stent alone (6.7%)...
  17. ncbi request reprint [Anti-thrombotic therapy of acute coronary syndromes without ST elevation]
    Gilles Montalescot
    Institut de Cardiologie, Groupe Hospitalier Pitie Salpetriere, AP HP, 47, Boulevard de l Hopital, 75013 Paris
    Bull Acad Natl Med 189:217-25; discussion 225-6. 2005
    ..Combined antithrombotic therapy also increases the benefit of early invasive strategies including coronary angiogram with stent-based percutaneous coronary angioplasty...
  18. doi request reprint Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
    Gilles Montalescot
    Bureau 2 236, Institut de Cardiologie, Hopital Pitie Salpetriere, 47 Boulevard de l Hopital, Paris, France
    Eur Heart J 30:2733-41. 2009
    ..This study investigated the effects of irbesartan vs. enalapril, with early vs. late treatment, on markers of inflammation and ischaemic heart disease in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS)...
  19. ncbi request reprint Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin
    G Montalescot
    Institut de Cardiologie, Pitie Salpetriere Hospital, Paris, France
    Circulation 110:392-8. 2004
    ....
  20. ncbi request reprint Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational global registry of acute coronary events
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire, Pitié Salptrière, Paris, France
    Am J Cardiol 95:1397-403. 2005
    ....
  21. ncbi request reprint Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes
    J P Collet
    Institute of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circulation 110:2361-7. 2004
    ..How prior use or recent discontinuation of OAA affects clinical presentation of acute coronary syndromes (ACS) and clinical outcomes (death, myocardial infarction [MI]) is unclear...
  22. ncbi request reprint Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes
    J P Collet
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Am Heart J 147:655-61. 2004
    ..Subcutaneous enoxaparin during at least 48 hours provides adequate anticoagulation and good clinical results in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention (PCI)...
  23. ncbi request reprint Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis
    J P Collet
    Department of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 26:2567-73. 2006
    ..Hypofibrinolysis promotes atherosclerosis progression and recurrent ischemic events in premature coronary artery disease. We investigated the role of fibrin physical properties in this particular setting...
  24. ncbi request reprint Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis
    J P Collet
    Department of Cardiology, Hematology Research Center, Pitie Salpetriere Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 21:142-8. 2001
    ..These findings provide new mechanistic information on reperfusion therapy...
  25. ncbi request reprint Characteristics and prognosis of patients with angiographic stent thrombosis: comparison between drug-eluting and bare-metal stents
    C Le Feuvre
    Institut de Cardiologie, Département de cardiologie médicale, Groupe Hospitalier Pitie Salpetriere, Paris
    Arch Cardiovasc Dis 101:220-5. 2008
    ..Conflicting data exist on the risk of stent thrombosis with drug-eluting stents (DES) versus bare-metal stents (BMS). Little is known about the potential different characteristics and outcomes of DES versus BMS thrombosis...
  26. ncbi request reprint Current antiplatelet options for NSTE-ACS patients
    G Cayla
    Institut de Cardiologie, bureau 236, Pitie Salpetriere University Hospital, 47 83, bld de l Hôpital, 75013 Paris, France
    QJM 105:935-48. 2012
    ....
  27. ncbi request reprint Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
    J P Collet
    Department of Cardiology, , Paris, France
    Circulation 103:658-63. 2001
    ..3%). CONCLUSIONS: PCI within 8 hours of the last enoxaparin subcutaneous injection seems to be safe and effective. The safety of subcutaneous LMW heparin in combination with platelet glycoprotein IIb/IIIa blockade awaits further study...
  28. ncbi request reprint Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality
    J P Collet
    Institut de Cardiologie, Pitie Salpetriere Hospital, Paris, France
    Circulation 108:391-4. 2003
    ..The present study was designed to assess the acute release of these markers in ST-segment elevation myocardial infarction (STEMI) and their relations to death...
  29. ncbi request reprint [Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase]
    C Adrie
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 88:1863-8. 1995
    ....
  30. ncbi request reprint [Role of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes]
    R Choussat
    Institut de Cardiologie, Hopital de la Pitie Salpetriere, 43, Boulevard de l Hopital, 75013 Paris, France
    Ann Cardiol Angeiol (Paris) 52:1s-9s. 2003
    ..Based on these results, the current therapeutic guidelines for clinical practice issued by the American and European cardiology societies are given in the conclusion, with their level of evidence...
  31. ncbi request reprint Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
    J P Collet
    Department of Cardiology, , Paris
    Circulation 103:2328-31. 2001
    ..These modifications could participate in the better coronary artery patency observed with abciximab...
  32. ncbi request reprint Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy
    J P Collet
    Department of Cardiology, Hemostasis Laboratory, Pitie Salpetriere Hospital, Hotel Dieu Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 20:1354-61. 2000
    ..Furthermore, these results provide a clear explanation for the hypofibrinolysis related to a defective fibrin architecture as described in venous thromboembolism and in premature coronary artery disease...
  33. ncbi request reprint Revascularization strategies in acute myocardial infarction: a meta-analysis
    A Bouzamondo
    Pharmacology Department, Pitie Salpetriere Hospital, Paris, France
    Int J Clin Pharmacol Ther 42:663-71. 2004
    ....
  34. ncbi request reprint Medium-term survival after primary angioplasty for myocardial infarction complicated by cardiogenic shock after the age of 75 years
    A Samadi
    Institut de Cardiologie, Département de cardiologie médicale, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris Cedex 13
    Arch Cardiovasc Dis 101:175-80. 2008
    ....
  35. doi request reprint Optimal time for catheterization in NSTE-ACS patients with impaired renal function: insights from the ABOARD Study
    O Barthelemy
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Universite Paris 6, INSERM CMR 937, Paris, France
    Int J Cardiol 167:2646-52. 2013
    ..To assess the impact of impaired renal function (IRF) and timing of catheterization (immediate versus delayed intervention) on outcomes in intermediate/high risk NSTE-ACS patients...
  36. ncbi request reprint [Treatment of intracoronary thrombus in the catheterisation laboratory in acute coronary syndrome patients]
    J P Collet
    Institut de Cardiologie, centre hospitalier universitaire de la Pitié Salpêtrière, APHP, 47, Boulevard de l Hopital, 75013 Paris, France
    Ann Cardiol Angeiol (Paris) 56:250-6. 2007
    ..A careful identification of all potential relevant causes is the key point of the management strategy. Post-PCI rethrombosis is the third situation and probably the less frequent. However, it is the most difficult to deal with...
  37. doi request reprint Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study
    G Cayla
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Heart 97:887-91. 2011
    ....
  38. pmc Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery
    M Faraggi
    Nuclear Medicine Department, Bichat Hospital, 46, rue Henri Huchard, F75018, Paris, France
    Heart 81:424-30. 1999
    ..The spontaneous changes in rest-redistribution thallium defect size were prospectively studied over six months in 52 patients with chronic Q wave myocardial infarction...
  39. ncbi request reprint Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, Paris, France
    J Am Coll Cardiol 41:8-14. 2003
    ....
  40. doi request reprint [Management of ST-elevation myocardial infarction in 2012]
    G Cayla
    Service de cardiologie, Universite Montpellier 1, CHU de Nimes, 1, Place du Pr DEBRE, 30029 Nimes Cedex, France
    Ann Cardiol Angeiol (Paris) 61:447-52. 2012
    ....
  41. ncbi request reprint [Effects of ultrasonic energy on blood clots in vitro]
    G Drobinski
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 86:915-20. 1993
    ..Ultrasonic energy could provide an alternative treatment for thrombotic vascular occlusion provided that more flexible guide wires could be designed...
  42. ncbi request reprint Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients
    F Mentre
    INSERM U436, Génétique Cardiovasculaire Centre Hospitalo Universitaire Pitié Salpêtrière, Paris, France
    Clin Pharmacol Ther 63:64-78. 1998
    ..Fluindione is a vitamin K antagonist with a long half-life. This study was designed to investigate the pharmacokinetics and pharmacodynamics of multiple doses of fluindione in patients...
  43. ncbi request reprint [FACT: French national registry of acute coronary syndromes. Specific study of French general hospital centers]
    J J Dujardin
    Service de cardiologie, centre hospitalier de Douai, BP 740, Douai cedex 59507, France
    Ann Cardiol Angeiol (Paris) 52:337-43. 2003
    ..The FACT registry is currently the French registry including the greatest number of patients with acute coronary syndromes...
  44. doi request reprint Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction
    Olivier Barthelemy
    Institut de Cardiologie APHP, INSERM U856 and University of Paris 6, Pitie Salpetriere Hospital, Paris, France
    Am J Cardiol 104:904-9. 2009
    ..In conclusion, high hospital levels of CITP, a marker of collagen degradation and ventricular remodeling, are associated with late mortality and other serious clinical events after AMI...
  45. ncbi request reprint A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
    Remi Choussat
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    J Am Coll Cardiol 40:1943-50. 2002
    ....
  46. ncbi request reprint [Value of antimyosin monoclonal antibody scintigraphy in the diagnosis of acute myocardial infarction]
    P Amoyal
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 85:359-61. 1992
    ..The diagnosis of a non-Q wave infarct was confirmed by myocardial scintigraphy using antimyosin monoclonal antibodies labelled with Indium 111. The site and size of the necrosis were also determined by this non-invasive investigation...
  47. ncbi request reprint [Use of abciximab during coronary angioplasty]
    F Philippe
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 90:1645-50. 1997
    ..Utilization of abciximab would be supported by the Cost saving approach of the EPIC trial 3-years follow-up which showed presentation of the initial benefits...
  48. doi request reprint Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
    Gilles Montalescot
    Institut de Cardiologie, CHU Pitié Salpêtrière AP HP, Universite Paris 6, Paris, France
    Lancet 378:693-703. 2011
    ..We compared traditional heparin treatment with intravenous enoxaparin in primary PCI...
  49. ncbi request reprint [Hyperhomocysteinemia in coronary artery diseases. Apropos of a study on 102 patients]
    J Blacher
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 89:1241-6. 1996
    ..The treatment of hyperhomocysteinaemia by folic acid supplements is effective in correcting plasma levels, without side effects and at a relatively low cost...
  50. doi request reprint Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates
    Farzin Beygui
    Department of Cardiology and INSERM, Pitié Salpêtrière University Hospital APHP, Paris, France
    Am J Cardiol 106:650-8. 2010
    ..In low-risk populations, a strategy using these biomarkers might help in identifying patients at greater risk of additional events...
  51. ncbi request reprint [Peripheral calcific embolism after percutaneous mitral valvuloplasty]
    G Montalescot
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 85:905-7. 1992
    ..The nature of the embolism was confirmed by anatomopathological examination after popliteal embolectomy. This complication would appear to be extremely rare but represents an additional risk in patients with calcific mitral stenosis...
  52. ncbi request reprint [Review and future perspectives on low-molecular-weight heparin]
    J P Collet
    Service de cardiologie, , 47, , 75013 Paris
    Arch Mal Coeur Vaiss 94:1233-42. 2001
    ..Development of a biological assay for monitoring either LMWH or GP IIb/IIIa receptor antagonists is another important issue in the setting of antithrombotic combinations which are now commonplace...
  53. ncbi request reprint [Postinfarction hibernating myocardium]
    G Montalescot
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 87:79-84. 1994
    ..Adequate revascularisation of necrosed territories depends on a deeper understanding and more precise prospective assessment of postinfarction hibernating myocardium...
  54. ncbi request reprint Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis
    M Dalby
    Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Circulation 108:1809-14. 2003
    ..Our objective was to gather all available information from clinical trials comparing transfer of patients experiencing AMI for angioplasty versus immediate thrombolysis...
  55. ncbi request reprint [Antithrombotics and interventional cardiology]
    J P Collet
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 92:1667-79. 1999
    ..Global evaluation of the clinical benefits should be advocated with a register of ischaemic and serious haemorrhagic events amongst the criteria of evaluation of the trials...
  56. ncbi request reprint [Prevalence of asymptomatic atherothrombotic lesions and risk of vascular events in patients with documented coronary artery disease]
    J P Collet
    Institut de Cardiologie, Hopital Pitie Salpetriere, Paris
    Arch Mal Coeur Vaiss 98:31-54. 2005
    ..Finally, the potential benefit in terms of therapeutic intervention of such screening needs to be evaluated. These important issues warrant further clinical studies with appropriate design...
  57. doi request reprint Platelet function testing and implications for clinical practice
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    J Cardiovasc Pharmacol Ther 14:157-69. 2009
    ....
  58. doi request reprint Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial
    Jean Philippe Collet
    Inserm unit 937, Institut de Cardiologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, bureau 236, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:485-96. 2009
    ..Late discontinuation of clopidogrel after an acute coronary syndrome or stent placement may be associated with a clinical rebound effect...
  59. ncbi request reprint Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
    Jean Philippe Collet
    Department of Cardiology, Centre Hôpital Pitié Salpêtrière, Bureau 2 236, 47, Boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 26:2285-93. 2005
    ..To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status...
  60. ncbi request reprint Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel
    Miles Dalby
    Institut de Cardiologie, Pitie Salpetriere University Hospital, Paris, France
    J Am Coll Cardiol 43:162-8. 2004
    ..The present study hypothesis was that eptifibatide offered further antiplatelet efficacy above clopidogrel in non-ST-elevation myocardial infarction (NSTEMI) patients before an expeditive coronary intervention...
  61. doi request reprint Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay
    J Abtan
    Gilles Montalescot, MD, PhD, bureau 236, Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 83 boulevard de l Hopital, 75013 Paris, France, Tel 33 142163006, Fax 33 142162931, E mail
    Thromb Haemost 110:1055-64. 2013
    ..In conclusion, ELISA-VASP is a fast, easy-to-use and specific test to identify HPR in ACS patients on thienopyridines. A 60% threshold value displays the best accuracy to identify HPR in these patients. ..
  62. ncbi request reprint [The value of active stents for coronary angioplasty in patients with chronic renal failure]
    G Phelippeau
    AP HP, Département de cardiologie médicale, Institut de Cardiologie, Groupe Hospitalier La Pitié Salpêtrière, Paris
    Arch Mal Coeur Vaiss 99:791-7. 2006
    ..Conclusions: In this study, coronary angioplasty with an active stent in patients with chronic renal failure was associated with a lower mortality rate compared with inactive stents, with no increase in the risk of acute thrombosis...
  63. ncbi request reprint [Effects of ultrasound energy on femoral artery occlusion. Angiographic and angioscopic results]
    G Drobinski
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 86:1331-6. 1993
    ..The manoeuverability of the guide wire and the relatively small size of the round distal tip explain why not all the thrombi could be treated.(ABSTRACT TRUNCATED AT 250 WORDS)..
  64. ncbi request reprint [Neurohormonal profile in aortic valve stenosis]
    J F Ramirez-Gil
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 86:1001-7. 1993
    ..8 +/- 42.3 pg/ml if W/M was decreased versus 82.7 +/- 15.4 pg/ml when W/M was normal): this could be related to the degree of left ventricular hypertrophy...
  65. ncbi request reprint [Non-ST acute coronary syndromes]
    J Ph Collet
    Institut de Cardiologie, Groupe Hospitalier La Pitié Salpêtrière, AP HP, 47, Boulevard de l Hopital, 75013 Paris
    Arch Mal Coeur Vaiss 95:37-42. 2002
    ..This combined antithrombotic also allowed to increase the benefit of an early invasive strategy including coronary angiogram with stent percutaneous coronary intervention...
  66. ncbi request reprint P2Y12 inhibitors: thienopyridines and direct oral inhibitors
    J P Collet
    INSERM U937 Unit, Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    Hamostaseologie 29:339-48. 2009
    ..Future rational use of these agents will require attention to disease and patient features to strike the optimal balance of benefit to risk...
  67. ncbi request reprint [Management coronary syndrome in the acute phase]
    J P Collet
    Institut de Cardiologie, Groupe Hospitalier Pitie Salpetriere, AP HP, 47 Boulevard de l Hopital, Paris, France
    Ann Cardiol Angeiol (Paris) 56:S21-8. 2007
    ..Providing adequate answers to these relevant clinical issues should improve the clinical benefit of clopidogrel. All these important points are discussed in the following manuscript...
  68. ncbi request reprint [Coronary restenosis: the cardiologist facing problems of definitions]
    P Charron
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 88:13-9. 1995
    ..4% of the stenosis studied, there measuring 44 to 64%. The judgement of the cathetiser of these intermediary stenoses was essentially influenced by the recurrence of angina during follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)..
  69. ncbi request reprint [Development of left ventricular function following aortic valve replacement]
    G Montalescot
    Service de cardiologie, , Paris
    Arch Mal Coeur Vaiss 81:485-92. 1988
    ..Thus, with this little obstructive prosthesis the postoperative improvement obtained persisted for five years in most cases of aortic valve stenosis or regurgitation...
  70. ncbi request reprint REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year
    P Sabouret
    Service de cardiologie, Groupe Hospitalier Pitie Salpetriere, Paris
    Arch Cardiovasc Dis 101:81-8. 2008
    ..It is the main cause of death in Western populations, a major public health concern and its prevalence will further increase in the future...
  71. ncbi request reprint Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference
    Farzin Beygui
    Department of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Circulation 113:e21-3. 2006
  72. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...
  73. ncbi request reprint Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
    Gilles Montalescot
    Institute of Cardiology, INSERM U856, Universite Paris 6, Pitié Salpêtrière Hospital AP HP, Paris, France
    Lancet 373:723-31. 2009
    ..Prasugrel, a potent and rapid-acting thienopyridine, is a potential alternative to clopidogrel. We aimed to assess prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) for STEMI...
  74. ncbi request reprint Modeling INR data to predict maintenance fluindione dosage
    E Comets
    INSERM U436, Modélisation mathématique et statistique en biologie et médecine, Institut de Physiopathologie et de Génétique Cardiovasculaire, Centre Hôpital Universitaire Pitié Salpêtrière, Paris, France
    Ther Drug Monit 20:631-9. 1998
    ..A Bayesian method for individualization of dosage regimen was developed, based on a risk function for INR at steady state. Prescription rules for fluindione were derived using this method retrospectively on the 73 patients in this study...
  75. doi request reprint Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis
    Franck Boccara
    Department of Cardiology, Saint Antoine Hospital, 184 rue du Faubourg St Antoine, Univ Paris 6, Paris, France
    Eur Heart J 32:41-50. 2011
    ..We sought to compare coronary risk factors, angiographic features, acute results of percutaneous coronary intervention, in-hospital outcomes, and pre-specified 1 year prognosis of HIV-infected and HIV-uninfected patients with ACS...
  76. doi request reprint Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure. The AERER study
    G Cayla
    Institut de Cardiologie, Pitie Salpetriere University Hospital, 75013 Paris, France
    Thromb Haemost 105:1024-31. 2011
    ..These improvements may explain the observed reduction in acute coronary syndrome following the implementation of the smoke-free legislation...
  77. ncbi request reprint [Screening strategies for the diagnosis of asymptomatic arterial lesions in patients with atherothrombosis]
    O Varenne
    Service de cardiologie, Hopital Cochin, Paris
    Arch Mal Coeur Vaiss 98:5-14. 2005
    ..Despite its invasive caracteristic, coronarory angiography remains the gold-standard for the diagnosis of coronary artery disease. However, cardiac multi-slices CT-scan appears a promising technique for asymptomatic patients...
  78. ncbi request reprint [Present and future developments of antithrombotic agents]
    G Montalescot
    Institut de Cardiologie, Groupe Hospitalier La Pitié Salpêtrière, Paris
    Arch Mal Coeur Vaiss 99:17-22. 2006
    ..Synthetic factor Xa inhibitors are at an early stage of development. Of the direct thrombin antagonists, bivalirudine provides an improved benefit/risk ratio and is a new option in the catheter laboratory...
  79. ncbi request reprint Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate
    J P Collet
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Arterioscler Thromb Vasc Biol 24:382-6. 2004
    ..This gammaA/gamma' fibrin is more resistant to lysis than gammaA/gammaA fibrin. Whether the physical properties of gamma' and gammaA fibrin may account for the difference in their fibrinolysis rate remains to be established...
  80. doi request reprint Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test
    Johanne Silvain
    Institut de Cardiologie, Institut National de la Santé et de la Recherche Médicale INSERM CMR937, Pitié Salpêtrière Hospital AP HP, Universite Paris 6, Paris, France
    J Am Coll Cardiol 55:617-25. 2010
    ..This study evaluated the ability of the bedside test Hemochron Jr. Hemonox (International Technidyne Corporation, Edison, New Jersey) to identify patients with insufficient anti-Xa activity level in the catheterization laboratory...
  81. ncbi request reprint Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction
    Pascal Lim
    Department of Cardiology, Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, Creteil, France
    Clin Chem 53:1835-40. 2007
    ..We investigated the association between plasma fetuin-A and clinical outcome after ST-elevation acute myocardial infarction (STEMI)...
  82. ncbi request reprint Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
    Jean Sebastien Hulot
    Pharmacology Department, Institute of Cardiology, Pitie Salpetriere University Hospital, Paris, France
    Clin Pharmacol Ther 77:542-52. 2005
    ..However, little dosing information is available regarding the use of enoxaparin in patients with renal impairment...
  83. doi request reprint Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    Laurent Bonello
    Department of Cardiology, Institut National de la Santè et de la Recherche Médicale Unité Mixte de Recherche 608, Hopital Universitaire Nord, Faculte de Medecine, Marseille, France
    J Am Coll Cardiol 56:919-33. 2010
    ..This review provides a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and proposes how this measurement may be used in the future care of patients...
  84. ncbi request reprint The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes
    Jean Philippe Collet
    Institut de Cardiologie, Pitie Salpetriere University Hospital, 47 Boulevard de l Hopital, 75013 Paris, France
    Diab Vasc Dis Res 2:136-43. 2005
    ..This review examines all these important issues...
  85. doi request reprint Real-life management of dual antiplatelet therapy interruption: the REGINA survey
    Jean Philippe Collet
    bureau 236, Inserm 937, Institut de Cardiologie, hôpital Pitié Salpêtrière AP HP, 47, Boulevard de l Hopital, 75013 Paris, France
    Arch Cardiovasc Dis 102:697-710. 2009
    ..The nationwide REGINA survey was designed to evaluate how the interruption of dual APT is managed in the 'real world'...
  86. ncbi request reprint [Fibreoptic bronchoscopy and anti-platelet agents: a risk-benefit analysis]
    V Trosini-Desert
    Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Service de Pneumologie et Reanimation, Paris, France
    Rev Mal Respir 24:48-56. 2007
    ..It is necessary therefore to weigh the indications for bronchoscopy and the subsequent benefits against the risks, not only of haemorrhage, but of thrombosis if the APAs are withdrawn...
  87. ncbi request reprint [Does diabetes affect the choice of pharmaceutical treatment in coronary artery disease?]
    J P Collet
    Institut de Cardiologie, group hospitalier La Pitié Salpêtrière, Paris
    Arch Mal Coeur Vaiss 97:51-7. 2004
    ..Finally, intravenous insulin therapy is promising in the initial phase of treatment of acute coronary syndromes with better defined blood glucose objectives...
  88. ncbi request reprint [Antithrombotics in pre-hospital phase of acute coronary syndromes]
    J P Collet
    Départment de Cardiogie, Institut de Cardiologie, Bureau
    Arch Mal Coeur Vaiss 98:1118-22. 2005
    ..It is also demonstrated that its clinical efficacy depends on the time delay between symptom onset and initiation of the therapy. However, the clinical benefit of prehospital administration remains to be established...
  89. ncbi request reprint A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots
    J Ph Collet
    Department of Cardiology, Pitie Salpetriere Hospital, Paris, France
    Circ Res 90:428-34. 2002
    ..These findings provide new insights on the synergistic potential of GP IIb/IIIa inhibitors and fibrinolytic agents...
  90. doi request reprint Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis
    Claude Le Feuvre
    Cardiology Department, Pitie Salpetriere Hospital, 47 et 83 Bd de l Hôpital, 75651 Paris Cedex 13, France
    Int J Cardiol 140:219-25. 2010
    ..Limited data is available on the long-term outcome after sirolimus-eluting stent (SES) implantation for in-stent restenosis...
  91. ncbi request reprint Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment
    Jean Sebastien Hulot
    Pharmacology Department, Pitie Salpetriere University Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Ther Drug Monit 26:305-10. 2004
    ....
  92. doi request reprint Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    Jean Philippe Collet
    Institut de Cardiologie, INSERM 856, Universite Paris 6, hôpital Pitié Salpêtrière AP HP, Paris, France
    Lancet 373:309-17. 2009
    ..We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel...
  93. ncbi request reprint [Platelet aggregation and antiplatelet agents in acute coronary syndromes]
    Jean Philippe Collet
    Institut de Cardiologie, Hopital de la Pitie Salpetriere, 47, Boulevard de l Hopital, 75013 Paris, France
    Med Sci (Paris) 20:291-7. 2004
    ..Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients...
  94. ncbi request reprint Does preoperative coronary angioplasty improve perioperative cardiac outcome?
    Gilles Godet
    Anesthesiology and Critical Care, Hospitalo Universitaire Pitié Salpêtrière, 47 Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Anesthesiology 102:739-46. 2005
    ..However, the impact of this approach on postoperative outcome remains controversial...
  95. ncbi request reprint Defining standards of care for facilitated and direct percutaneous coronary intervention
    Gilles Montalescot
    Division of Cardiology, Hĵpital la Pitié Salpétrière, Institut de Cardialogie, Paris, France
    Clin Cardiol 25:I27-32. 2002
    ..Since direct PCI is often a slow process, better use of existing and future therapies, as well as advances in patient transport, are expected to improve patient outcomes...
  96. ncbi request reprint Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
    Ziad Mallat
    Institut National de la Santé et la Recherche Médicale, INSERM U541, Institut Fédératif de Recherche IRF Circulation, Paris, France
    J Am Coll Cardiol 46:1249-57. 2005
    ..The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS)...
  97. pmc The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis
    Jean Philippe Collet
    Institut de Cardiologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, France
    Blood 106:3824-30. 2005
    ..In conclusion, these studies provide the first definitive evidence that the alphaC domains play an important role in determining the structure and biophysical properties of clots and their susceptibility to fibrinolysis...
  98. ncbi request reprint Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis
    Claude Le Feuvre
    Cardiology Department, Pitie Salpetriere Hospital, Paris, France
    Int J Cardiol 109:207-12. 2006
    ..This study aimed to assess the clinical outcome and to analyse predictive factors of cardiac events in patients with in-stent restenosis treated with Sirolimus-eluting stent (SES)...
  99. doi request reprint Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
    Gilles Montalescot
    Institut de Cardiologie, Bureau 2 236, Centre Hospitalier Universitaire Pitie Salpetriere, 47 Boulevard de l Hopital, 75013 Paris, France
    JAMA 302:947-54. 2009
    ..International guidelines recommend an early invasive strategy for patients with high-risk acute coronary syndromes without ST-segment elevation, but the optimal timing of intervention is uncertain...
  100. ncbi request reprint Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots
    Jean Philippe Collet
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière AP HP, 47 Boulevard de l Hopital, 75013 Paris, France
    J Biol Chem 278:21331-5. 2003
    ....